Jazz Reports the Initiation of Epidiolex/Epidyolex (cannabidiol) in P-III (GWEP20238) Trial for Epilepsy Associated with Myoclonic-Atonic Seizures
- The company has initiated a new 2-part P-III (GWEP20238) trial to evaluate the efficacy and safety of Epidiolex vs PBO in children & adolescents aged 1-18yrs. with EMAS at 30 global sites
- The study will determine EMAS-associated seizure frequency over the 14wk. treatment period compared to baseline. Part A will evaluate the effectiveness and safety of cannabidiol as an adjunctive treatment for MAS over PBO. Patients will get an option to continue in a 54wk. OLE (part B), following the completion of part A
- Preliminary results from the clinical development program, incl. RWE which supports cannabidiol as an effective therapy for myoclonic-atonic-associated seizures led to the start of the P-III trial
Ref: Jazz Pharma | Image: Jazz Pharma
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.